The industry believes that it may be possible to form a competitive advantage for enterprises in terms of technology, influence, transformation, and other aspects, in order to stand out in the market.

In terms of technology, it mainly refers to improving technology and saving costs. It is reported that the process route of pharmaceutical intermediates is long, there are multiple reaction steps, and the amount of solvent used is large, with great potential for technological improvement.

For example, lower value raw materials can be used to replace higher value raw materials, such as replacing liquid bromine in the production of aminothiazide acid, and using ammonium thiocyanate instead of potassium thiocyanate (sodium) in production.

In addition, a single solvent can also be used instead of different solvents in the reaction process to recover the alcohols generated by the hydrolysis of ester products.

In terms of influence, the main focus is to form our own unique products and enhance our industry influence. It is understood that due to the severe homogenization competition in China's pharmaceutical intermediate industry, if enterprises can create their own advantageous products, they will inevitably have a greater advantage in the market.

In terms of transformation, currently, with stricter environmental protection requirements in China, resources are inclined towards high value-added industries, and with the increase in environmental protection costs, transformation has become a problem that pharmaceutical intermediate enterprises have to consider for sustainable development.

It is recommended that pharmaceutical intermediate enterprises extend their industrial chain upstream and downstream, and switch their main raw materials to self production. This can further reduce costs, and for some special raw materials, it can play a role in avoiding the monopoly of key raw materials.

The industry has stated that the downward extension involves the direct synthesis of pharmaceutical intermediates into raw materials, which can further increase the added value of products and sell them directly to pharmaceutical companies. It is worth noting that extending downstream requires significant investment and high production technology requirements, as well as maintaining good relationships with manufacturers of raw materials.

In addition, research and development is of great significance for the intermediate industry, and currently, the pharmaceutical intermediate industry in China generally places low emphasis on research and development. Therefore, in an environment where technological requirements continue to improve, efficient R&D enterprises with strong R&D capabilities will stand out, while small and medium-sized enterprises without R&D capabilities may be eliminated by the market. In the future, the concentration of the industry will further increase, moving from the mid to low-end development stage to a higher stage of development.